Thursday, 20 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
10 Jun 2016 Social BMS Orencia data presented @ #EULAR16; including #CORRONA data showing RF+ or CCP+ assoc w/ better Orencia responses https://t.co/EHiE9G7x7N
29 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/OlN3Eyqya4
30 Apr 2015 Social Negative RCT of RTX vs PBO in pts w/ ITP (PLT<30k) on background steroids. No difference in response or relapse rates http://buff.ly/1HHoCni 
14 Jun 2018 Social RT @jomargwhite: MTX associated with reduction of CVD risk in patients reviving biologic treatment #eular2018 #methotrexate https://t.co/sl…
23 Aug 2016 Social Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
17 Jun 2019 Social Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
20 Jul 2018 Social RT @AngusWorthing: FDA releases #biosimilars action plan. @ACRheum through AMA has pushed FDA to finalize interchangeability pathway. Fing…
06 Aug 2018 Social Psoriasis biologic pipeline continues to grow. In development are IL-23 inhibitors (risankizumab, mirikizumab) & the IL-17 A/F inhbitor (bimekizumab). Tildrakizumab and certolizumab were approved for Psoriasis earlier in 2018. https://t.co/QFbdtO1Lua
19 Aug 2017 Social RheumNow Wk in Review up! How to store enbrel, over/under testing. Check out podcast https://t.co/I5b8tFK7Oa video https://t.co/rJ2nMY6woD
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/iYAzWwsyi2
06 Aug 2019 Social FDA has approved Turalio (pexidartinib) for the treatment of adults with the rare disorder, tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. https://t.co/eMTmFSW97A
07 Dec 2017 Social Prospective study of 133 IBD pts (64% CD, 36% UC) switched from Remicade to biosimilar Inflectra. After 12 mos. no differences in drug levels, disease activity between innovator and biosimilar. https://t.co/QEH3lUaXD4
07 Apr 2017 Social Dr. Laura Cappelli - Talk on checkpoint inhibitors of PD-1 (nivolumab, pembrolizumab) and CTLA4 (impilimumab) commonly used in chemotherapy
06 Jul 2015 Social Pfizer has submitted to the FDA (for review) a new once-a-day Xeljanz (tofacitinib) 11 mg qd (equal to 5 mg bid) http://t.co/a3HI2akJEr
03 Oct 2018 Social RT @RheumNow: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheum…
13 Sep 2017 Social Sandoz announces FDA will review its biosimilar version of rituximab https://t.co/80E1jopxqd
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA) https://t.co/xmAuMJN4Gd
22 Nov 2016 Social RT @DrPetryna: Sarilumab (IL6R) superior to Humira in MONARCH phase 3 trial. neutropenia &abn LFT > with sarilumab https://t.co/2Rwxz8hiZQ…